ArticleScientific reports2021
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- LSD increases sleep duration the night after microdosing.Translational psychiatry · 2024Trial
- Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.Translational psychiatry · 2022Trial
- Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults.American journal of preventive medicine · 2026Article
- A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A contemporary exploration of motivations and practices of psychedelic use among emerging adult cannabis users in the United States: A qualitative analysis.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2026Article
- Tryptamine from wake-active monoaminergic neurons regulates sleep homeostasis.Nature neuroscience · 2026Article
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.Biomolecules · 2026Review
- Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study.Drug and alcohol review · 2026Article
- Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.BJPsych open · 2026Article
- Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use.Scientific reports · 2026Article
- Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.Brain sciences · 2025Review
- Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.Journal of eating disorders · 2025Article
- Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?Neurobiology of stress · 2025Review
- ExploringJournal of fungi (Basel, Switzerland) · 2025Review
- Article
- Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.Neuropsychiatric disease and treatment · 2025Review
- Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.Journal of psychopharmacology (Oxford, England) · 2024Review
- Unlocking the self: Can microdosing psychedelics make one feel more authentic?Nordisk alkohol- & narkotikatidskrift : NAT · 2024Article
- Psilocybin for the treatment of Alzheimer's disease.Frontiers in neuroscience · 2024Review
- Does LSD confer lasting psychological resilience? an investigation of naturalistic users experiencing job loss.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of psychedelic substances at sub-sensorium 'microdoses', has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers (n = 4050) and non-microdosers (n = 4653) via a mobile application. Psilocybin was the most commonly used microdose substances in our sample (85%) and we identified diverse microdose practices with regard to dosage, frequency, and the practice of stacking which involves combining psilocybin with non-psychedelic substances such as Lion's Mane mushrooms, chocolate, and niacin. Microdosers were generally similar to non-microdosing controls with regard to demographics, but were more likely to report a history of mental health concerns. Among individuals reporting mental health concerns, microdosers exhibited lower levels of depression, anxiety, and stress across gender. Health and wellness-related motives were the most prominent motives across microdosers in general, and were more prominent among females and among individuals who reported mental health concerns. Our results indicate health and wellness motives and perceived mental health benefits among microdosers, and highlight the need for further research into the mental health consequences of microdosing including studies with rigorous longitudinal designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.